Abpro Holdings (ABP) investor relations material

Company overview and business model

• Focuses on developing next-generation antibody therapeutics for severe diseases, primarily in immuno-oncology and ophthalmology, leveraging proprietary DiversImmune® and MultiMab™ platforms.

• Lead candidates ABP-102 (HER2/CD3 T-cell engager for solid tumors) and ABP-201 (VEGF/ANG-2 inhibitor for eye diseases) are in preclinical stages, with clinical trials planned for 2026.

• Operates through collaborations with global pharmaceutical partners, including Celltrion and Abpro Bio, and holds worldwide or territorial rights to its pipeline assets.

• Business model includes licensing, milestone payments, royalties, and profit-sharing from partnered programs.

Financial performance and metrics

• As of September 30, 2025, accumulated deficit was $124.6 million; net loss was $8.5 million for the nine months ended September 30, 2025, and $7.2 million for the year ended December 31, 2024.

• Revenue is minimal, with $0.2 million recognized in 2024 from research services; no product sales to date.

• Operating expenses decreased due to reduced R&D activity and headcount; cash balance as of September 30, 2025, was $328,000.

• Company has restated prior financials due to errors in accrued expenses and identified material weaknesses in internal controls.

Use of proceeds and capital allocation

• May receive up to $50 million in gross proceeds from the Standby Equity Purchase Agreement (SEPA) with YA II PN, Ltd.; proceeds intended for working capital and general corporate purposes.

• Management has broad discretion over use of funds; actual allocation will depend on operational needs and market conditions.